

Minireview Article

Interrelationship between Non-alcoholic steatohepatitis and vitamin D:A Mini Review

Abstract

Non-alcoholic steatohepatitis (NASH) is a progressive liver disease characterized by inflammation and accumulation of fat in the liver, often associated with obesity, diabetes and metabolic syndrome leading to fibrosis and ultimately cirrhosis of the liver.

The literature search included original articles, randomized controlled trials, cohort studies, case-control studies and review articles from the year 2004 onwards. The electronic databases Cochrane, MEDLINE, ScienceDirect and PubMed were used for the literature search.

The current state of evidence shows a positive correlation between non-alcoholic steatohepatitis and vitamin D deficiency. The association between vitamin D and non-alcoholic steatohepatitis (NASH) is a complex one and further studies are needed for understanding this relationship. This review is aimed at the relationship between non-alcoholic steatohepatitis and vitamin D, additionally, it will discuss the role of vitamin D in modulating immune responses with its protective effects on the liver. The need for maintaining an adequate level of vitamin D in at-risk populations will also be discussed along with future research in this matter.

Keywords: Non-alcoholic steatohepatitis, NASH, Vitamin D, Liver fibrosis, Metabolic syndrome.

Introduction

Non-alcoholic steatohepatitis (NASH) is characterized by progressive liver damage, the role of vitamin D and other factors is vital for understanding the reasons for this progressive liver disease. Research has shown that non-alcoholic steatohepatitis is associated with low levels of vitamin D in individuals, as compared to the healthy controls, a positive correlation which may influence the disease outcome. (1)

The progression of non-alcoholic steatohepatitis to a severe form in a vitamin D deficiency state, suggests the role of vitamin D as a regulator of the immune system and inflammation, which needs to be further evaluated, leading to new therapeutics for intervention and management. (2)

Studies have suggested that addressing the deficiency of vitamin D through patient education and supplementation improves overall metabolic health, along with the reduction of hepatic inflammation in at-risk populations. (3)

Understanding Non-Alcoholic Steatohepatitis (NASH)

Non-alcoholic fatty liver disease (NAFLD) condition where there is an accumulation of fat in the liver but there is no tissue damage which may lead to non-alcoholic steatohepatitis characterized by tissue damage. Initially, the progression of the liver injury has no symptoms, however, by recognizing the risk factors such as obesity, diabetes, and dyslipidemia timely intervention can be carried out.

Non-alcoholic steatohepatitis causes progressive inflammation of the liver where there is excess fat accumulation in the liver which leads to liver damage, fibrosis and cirrhosis if left untreated. (4)

In the initial stage lifestyle modifications, dietary changes and increased physical activity may play a vital role in reversing the progression of non-alcoholic steatohepatitis and enhancing liver function. (5)

Many other pharmacological treatments are being formulated to target the mechanism of non-alcoholic steatohepatitis, offering hope for more effective interventions, research and studies are on to identify specific biomarkers that will help in the diagnosis and monitoring of non-alcoholic steatohepatitis, leading to personal treatment plans.

Lifestyle and dietary changes are important for improving the outcome of this condition and this in turn requires continuous patient education and a robust support system for promoting adherence to the plan of management. (6)

The Role of Vitamin D in Liver Health

Vitamin D in any form has been shown to have a protective effect on the liver and optimum levels of vitamin D levels may help in reducing the damage to the liver, caused by low vitamin D levels. (7)

The vitamin also helps in regulating insulin levels and increases insulin sensitivity in patients with non-alcoholic steatohepatitis, which is a metabolic dysfunction in patients with non-alcoholic steatohepatitis. The addition of vitamin D as a supplement in ongoing management could enhance the management of non-alcoholic steatohepatitis. (8)

Long-term effects of vitamin D on the management of non-alcoholic steatohepatitis need to be evaluated and guidelines need to be developed for evidence-based treatment.

Cost-effectiveness of the management remains a critical issue in the treatment of non-alcoholic steatohepatitis, so it becomes essential to monitor patient outcomes to formulate cost-effective strategies to integrate vitamin D in the management protocols. (9)

Exploring the Link Between Vitamin D Deficiency and Non-alcoholic steatohepatitis

By understanding the process of non-alcoholic steatohepatitis in a vitamin D deficiency state, the interventions can target the deficiency of the vitamin and also the process causing non-alcoholic steatohepatitis.

Understanding this relationship could lead to targeted interventions that not only address vitamin D deficiency but also mitigate the progression of non-alcoholic steatohepatitis. Furthermore, researchers are investigating the potential mechanisms by which vitamin D influences liver health, including its role in modulating immune responses and reducing oxidative stress. (8)

Clear guideline for the management of non-alcoholic steatohepatitis, by the use of vitamin D, needs to be established, and clinical trials are being designed to review and evaluate the role of vitamin D supplements in non-alcoholic steatohepatitis patients. (10).

These studies are also important to closely monitor the patients for long-term benefits and potential risks associated with the use of vitamin D in patients with non-alcoholic steatohepatitis. (11)

Moreover, understanding the relationship between vitamin D levels and metabolic factors could provide deeper insights into treatment approaches for non-alcoholic steatohepatitis, leading to improved patient care and outcomes.

Pathophysiology of Non-Alcoholic Steatohepatitis: Key Mechanisms

To understand the pathophysiology of non-alcoholic steatohepatitis it is important to understand the mechanisms including, lipid metabolism dysregulation, insulin resistance, and activation of inflammatory pathways that lead to liver damage. (12)

All these mechanisms interact in a very complex way, causing hepatocyte injury and inflammation that exacerbates the condition of non-alcoholic steatohepatitis. (13)

The alterations in gut microbiota, influence the metabolic health of the individuals as this leads to insulin resistance and also promotes inflammation which can further complicate the management of non-alcoholic steatohepatitis. Research is also focusing on the use of probiotics which can target the gut to restore the metabolic balance in the patients.

Mitochondrial dysfunction and oxidative stress are also seen as the potential factors contributing to the development of non-alcoholic steatohepatitis, which highlights the need for a more open-minded approach to the treatment which can address the underlying issues.

The extensive use of antioxidant agents that can reduce oxidative stress and restore mitochondrial function, could open new avenues for a better understanding of the problem with a favorable outcome. (13)

Clinical Implications of Vitamin D Deficiency in Non-alcoholic steatohepatitis Patients

As vitamin D is associated with metabolic disorders, its role in the development of non-alcoholic steatohepatitis is being recognized, studies have shown that adequate levels of vitamin D may help to mitigate insulin resistance and improve insulin sensitivity, which can make Vitamin D a potent adjuvant for patients suffering from this liver condition.

Supplementation with vitamin D could improve the efficacy of existing treatments with lifestyle modifications, leading to better management of liver health and overall metabolic function in patients. Vitamin D

improves insulin resistance in non-alcoholic fatty liver disease (NDLF) patients without the rise in aspartate aminotransferase levels (14)

Ongoing research is exploring the optimal dosing and timing of vitamin D supplementation to increase its benefits in this population, thus making supplementation more effective for management. The dose, frequency and duration of the supplementation are independently associated with plasma vitamin D levels, this relationship is important to optimize vitamin D levels in these patients. (15)

As the understanding of vitamin D's mechanisms continues to evolve, it may pave the way for innovative strategies in the prevention and treatment of non-alcoholic steatohepatitis, ultimately improving patient outcomes.

Current Research on Vitamin D Supplementation and Non-alcoholic steatohepatitis Outcomes

The long-term effects of vitamin D on patients is being evaluated by studying the metabolic parameters and histology of the liver which show a positive correlation. (16-17)

As these trials progress, there is a need to identify patient-specific populations that may benefit the most, from vitamin D treatment. If the researchers can identify such patient-specific populations, then the researchers are hopeful that they will define the optimal dosing regimens that may benefit this population.

Vitamin D has the potential to modulate insulin sensitivity and resistance, as this metabolic dysfunction has relevance with non-alcoholic steatohepatitis, the role of vitamin D in non-alcoholic steatohepatitis remains particularly relevant.

The strong association between vitamin D levels and gut microbiota is gaining attention in recent research works, suggesting that a holistic approach by supplementing probiotics may help the treatment and enhance outcomes for patients with non-alcoholic steatohepatitis. (18)

Further studies are needed to explore these relationships and determine how they can be leveraged to improve patient care and management strategies.

Potential therapeutic Strategies for managing Non-alcoholic steatohepatitis and Vitamin D Deficiency

Lifestyle modifications with increased physical activity pharmacological intervention, and integration of vitamin D supplements into the strategies may lead to a multifaceted approach to address both non-alcoholic steatohepatitis and vitamin D deficiency.

Additionally, ongoing research into the role of probiotics and prebiotics may further illuminate how gut health influences vitamin D metabolism and non-alcoholic steatohepatitis progression, paving the way for innovative treatment protocols (15), collaboration between healthcare providers, dieticians and nutritionists is essential in creating personalized plans that consider individual patient needs and preferences.

Obeticholic acid (OCA) was considered as agent for treatment of NASH, but further trials have not been approved by the FDA. (19)

Vitamin E or pioglitazone have been considered for the treatment of nonalcoholic steatohepatitis (NASH) with not-so-promising results and showed no improvement in the fibrosis score of the liver. (20)

Moreover, patient education and support systems will play a crucial role in empowering individuals to make sustainable lifestyle changes, fostering a proactive approach to their health management.

Future Directions in Non-alcoholic steatohepatitis Research: Vitamin D as a Target for Intervention

The association between vitamin D and non-alcoholic steatohepatitis is being explored and it's important to investigate the type of supplemental strategies and dosing regimens with the timing of vitamin D supplementation. (21)

The mechanism by which vitamin D levels influence liver metabolism and inflammation needs to be understood so that targeted therapies that can mitigate the progression of Non-alcoholic steatohepatitis can be developed.

Furthermore, clinical trials assessing the efficacy of vitamin D in diverse populations with different geographical and social factors will help to establish guidelines for its use in clinical practice. (22)

Moreover, the interplay between vitamin D levels and other metabolic factors, such as insulin resistance and obesity, social factors warrant further examination to fully elucidate its therapeutic potential in managing non-alcoholic steatohepatitis.

Discussion

Some studies show that the relationship between non-alcoholic steatohepatitis and Vitamin D Deficiency is important, but the approach should be with caution (23), as the assertion that low levels of vitamin D exacerbate liver inflammation and fibrosis lacks robust, conclusive evidence.

Many studies that link the role of vitamin D and non-alcoholic steatohepatitis, have overlooked the confounding variables such as co-existing medical conditions, geographical location where sunlight exposure is less, dietary habits, physical activity and other social activities which can damage the liver.

Some studies claim that the role of vitamin D is speculative as the studies have evaluated the correlation between the two without establishing a causative mechanism. (24)

The supplementation of vitamin D could be an adjunct for the treatment but can be an early assumption as there are many complexities of liver disease and the progression of non-alcoholic steatohepatitis multifactorial. (14)

The emphasis on vitamin D may divert attention from these more established interventions, like lifestyle modifications and increased physical activity with dietary changes. (15)

Focusing on vitamin D supplementation could lead to a simplistic view of a complex disease, undermining the importance of comprehensive lifestyle changes and pharmacological treatments that target the underlying mechanisms of non-alcoholic steatohepatitis (25), in addition to the proposed benefits of vitamin D in regulating insulin sensitivity and reducing inflammation should be viewed with skepticism. (23)

Over-reliance on vitamin D could detract from more effective strategies that address the root causes of metabolic dysfunction leading to liver damage, the implications of these findings could extend beyond non-alcoholic steatohepatitis, potentially influencing treatment strategies for other metabolic disorders.

The relationship between vitamin D and gut microbiota shows further insights into its impact on metabolic health, suggesting a multifaceted approach to treatment that incorporates lifestyle modifications alongside supplementation of vitamin D alone.

Investigating the role of vitamin D in modulating and down-regulating inflammatory responses may enhance the world's comprehension of its protective effects against liver damage and metabolic dysregulation and may give rise to more extensive studies (11)

The complexities of metabolic disorders need a holistic approach and for interdisciplinary collaboration in research, integrating insights from nutrition, microbiology, and immunology to develop treatment protocols that address the complexities of metabolic disorders leading to non-alcoholic steatohepatitis. (5)

To conclude, the role of vitamin D and non-alcoholic steatohepatitis is an area of research, and it is very crucial to maintain a balanced perspective that gives importance to the well-established treatment modalities and more clinical trials are required before endorsing vitamin D supplements as a standard treatment.

Conclusion

There is a complicated association between vitamin D and non-alcoholic Steatohepatitis, as a simple association cannot be explained. (26)

The current evidence suggests that low vitamin D levels may mitigate liver inflammation and fibrosis, thus influencing the progression of non-alcoholic steatohepatitis. (27)

To date, vitamin D is a promising agent for target intervention in patients with non-alcoholic steatohepatitis, for patient management, as non-alcoholic steatohepatitis has a multifactorial nature and is associated with metabolic dysfunction in affected individuals, it needs a holistic approach that will involve, pharmacological treatments, lifestyle modifications, and vitamin D supplements. Furthermore, the understanding of the association between vitamin D, insulin resistance and gut microbiota needs more evaluation as all these influence liver health. (18)

Only by addressing the critical gap areas, new and concrete treatment strategies can be developed that will enhance metabolic health and improve patient outcomes and quality of life.

The integration of interdisciplinary insights will be essential in developing comprehensive management plans that address the complexities of this condition, its associated metabolic disorders and vitamin D levels.

Disclaimer (Artificial intelligence)

Author(s) hereby declare that NO generative AI technologies such as Large Language Models (ChatGPT, COPILOT, etc.) and text-to-image generators have been used during the writing or editing of this manuscript.

References

1. Wang X, Li W, Zhang Y, Yang Y, Qin G. Association between vitamin D and non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: results from a meta-analysis. *International journal of clinical and experimental medicine*. 2015;8(10):17221
2. Pacifico L, Osborn JF, Bonci E, Pierimarchi P, Chiesa C. Association between vitamin D levels and nonalcoholic fatty liver disease: potential confounding variables. *Mini Reviews in Medicinal Chemistry*. 2019 Mar 1;19(4):310-32. <https://doi.org/10.2174/1389557518666181025153712>
3. Tsyryuk, O., Tseyslyer, Yu. V., Strubchevska, K., Kozyk, M., Ostapchenko, D., Korotkyi, O., & Tymoshenko, I. (2023). Relationship between vitamin D deficiency and metabolic disorders. *Mižnarodnij Endokrinologičnij Žurnal*. <https://doi.org/10.22141/2224-0721.19.1.2023.1241>

4. Bril, F., Maximos, M., Portillo-Sanchez, P., Portillo-Sanchez, P., Biernacki, D., Biernacki, D., Lomonaco, R., Lomonaco, R., Subbarayan, S., Subbarayan, S., Correa, M., Lo, M. C., Suman, A., & Cusi, K. (2015). Relationship of vitamin D with insulin resistance and disease severity in non-alcoholic steatohepatitis. *Journal of Hepatology*. <https://doi.org/10.1016/J.JHEP.2014.08.040>
5. Kitson, M. T., Pham, A., Gordon, A., Kemp, W., & Roberts, S. K. (2016). High-dose vitamin D supplementation and liver histology in NASH. *Gut*. <https://doi.org/10.1136/GUTJNL-2015-310417>
6. Livadariu, R. M., Timofte, D., Trifan, A., Danila, R., Ionescu, L., Am, S., & Ciobanu, D. (2018). Vitamin d deficiency, a noninvasive marker of steatohepatitis in patients with obesity and biopsy proven nonalcoholic fatty liver disease. *Acta Endocrinologica-Bucharest*. <https://doi.org/10.4183/AEB.2018.76>
7. Kasapoglu, B., Türkay, C., Yalçın, K. S., Carlioglu, A., Sözen, M., & Kektener, A. (2013). Low vitamin D levels are associated with increased risk for fatty liver disease among non-obese adults. *Clinical Medicine*. <https://doi.org/10.7861/CLINMEDICINE.13-6-576>
8. Geier, A. (2011). Shedding new light on vitamin D and fatty liver disease. *Journal of Hepatology*. <https://doi.org/10.1016/J.JHEP.2010.12.026>
9. Ratziu, V., Voiculescu, M., & Poynard, T. (2012). Touching some firm ground in the epidemiology of NASH. *Journal of Hepatology*. <https://doi.org/10.1016/J.JHEP.2011.08.002>
10. Quintero, P., & Arrese, M. (2013). Nuclear control of inflammation and fibrosis in nonalcoholic steatohepatitis: therapeutic potential of dual peroxisome proliferator-activated receptor alpha/delta agonism. *Hepatology*. <https://doi.org/10.1002/HEP.26582>
11. Spence, J. D. (2022). B vitamins for NASH: use methylcobalamin, not cyanocobalamin. *Journal of Hepatology*. <https://doi.org/10.1016/j.jhep.2022.08.019>
12. Marra, F., & Lotersztajn, S. (2013). Pathophysiology of NASH: perspectives for a targeted treatment. *Current Pharmaceutical Design*. <https://doi.org/10.2174/13816128113199990344>
13. Cao, Y., Shu, X., Yao, Z., Ji, G., & Zhang, L. (2020). Is vitamin D receptor a druggable target for non-alcoholic steatohepatitis? *World Journal of Gastroenterology*. <https://doi.org/10.3748/WJG.V26.I38.5812>
14. McCourt, D. M. (2022). Additional treatment of vitamin D for improvement of insulin resistance in non-alcoholic fatty liver disease patients: a systematic review and meta-analysis. *Dental Science Reports*. <https://doi.org/10.1038/s41598-022-11950-x>
15. Chao, Y.-S., Brunel, L., Faris, P., & Veugelers, P. J. (2013). The Importance of Dose, Frequency and Duration of Vitamin D Supplementation for Plasma 25-Hydroxyvitamin D. *Nutrients*. <https://doi.org/10.3390/NU5104067>
16. Rudolph, B., Selig, T., Li, Y., Ovchinsky, N., Kogan-Liberman, D., Liszewski, M. C., Levin, T. L., Ewart, M., Liu, Q., Viswanathan, S., Lin, J., Xue, X., Burk, R. D., & Strickler, H. D. (2021). Relationship of Vitamin D Deficiency and Fatty Liver in Children as Defined by Multiple Imaging and Histologic Endpoints. <https://doi.org/10.1097/PG9.0000000000000077>
17. Nobili, V., Giorgio, V., Liccardo, D., Bedogni, G., Morino, G., Alisi, A., & Cianfarani, S. (2014). Vitamin D levels and liver histological alterations in children with nonalcoholic fatty liver disease. *European Journal of Endocrinology*. <https://doi.org/10.1530/EJE-13-0609>
18. Ferolla, S. M., Armiliato, G. N. de A., Couto, C. A., & Ferrari, T. C. A. (2015). Probiotics as a complementary therapeutic approach in nonalcoholic fatty liver disease. *World Journal of Hepatology*. <https://doi.org/10.4254/WJH.V7.I3.559>

19. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Neuschwander-Tetri, Brent A et al. *The Lancet*, Volume 385, Issue 9972, 956 - 965
20. Greenhill, C. (2010). Vitamin E therapy for NASH? *Nature Reviews Gastroenterology & Hepatology*. <https://doi.org/10.1038/NGASTRO.2010.87>
21. Caldwell, S. H. (2017). NASH Therapy: omega 3 supplementation, vitamin E, insulin sensitizers and statin drugs. *Clinical and Molecular Hepatology*. <https://doi.org/10.3350/CMH.2017.0103>
22. Serfaty, L. (2019). Pharmacological treatment of NASH. *Presse Medicale*. <https://doi.org/10.1016/J.LPM.2019.09.015>
23. Barchetta, I., Del Ben, M., Angelico, F., Di Martino, M., Fraioli, A., La Torre, G., Saulle, R., Perri, L., Morini, S., Tiberti, C., Bertocchini, L., Cimini, F. A., Panimolle, F., Catalano, C., Baroni, M. G., Baroni, M. G., & Cavallo, M. G. (2016). No effects of oral vitamin D supplementation on non-alcoholic fatty liver disease in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial. *BMC Medicine*. <https://doi.org/10.1186/S12916-016-0638-Y>
24. Neuschwander-Tetri, B. A. (2009). Lifestyle Modification as the Primary Treatment of NASH. *Clinics in Liver Disease*. <https://doi.org/10.1016/J.CLD.2009.07.006>
25. Karatayli, E., Stokes, C. S., & Lammert, F. (2020). Vitamin D in Preclinical Models of Fatty Liver Disease. *Anticancer Research*. <https://doi.org/10.21873/ANTICANRES.13981>
26. Ludwig, J., McGill, D. B., & Lindor, K. D. (1997). REVIEW: Nonalcoholic steatohepatitis. *Journal of Gastroenterology and Hepatology*. <https://doi.org/10.1111/J.1440-1746.1997.TB00450.X>
27. Tabrizi, R., Moosazadeh, M., Bagheri Lankarani, K., Akbari, M., Heydari, S. T., Kollahdoz, F., Samimi, M., & Asemi, Z. (2017). The effects of vitamin D supplementation on metabolic profiles and liver function in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis of randomized controlled trials. *Diabetes and Metabolic Syndrome: Clinical Research and Reviews*. <https://doi.org/10.1016/J.DSX.2017.07.025>